InicioATHA • NASDAQ
add
Athira Pharma
Cierre anterior
0,32 $
Intervalo diario
0,32 $ - 0,34 $
Intervalo anual
0,30 $ - 3,67 $
Cap. bursátil
12,47 M USD
Volumen medio
243,16 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 15,57 M | -49,20 % |
Ingresos netos | -15,00 M | 45,01 % |
Margen de beneficio neto | — | — |
Beneficios por acción | — | — |
EBITDA | -15,32 M | 49,59 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 51,28 M | -65,22 % |
Activos totales | 58,78 M | -63,32 % |
Responsabilidades totales | 13,94 M | -53,63 % |
Patrimonio total | 44,84 M | — |
Acciones en circulación | 39,04 M | — |
Precio-valor contable | 0,28 | — |
Rentabilidad económica | -53,67 % | — |
Retorno sobre capital | -74,16 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -15,00 M | 45,01 % |
Efectivo de operaciones | -26,01 M | 1,06 % |
Efectivo de inversión | -2,81 M | -144,00 % |
Efectivo de financiación | 34,00 mil | -77,63 % |
Variación neta del flujo de caja | -28,79 M | -45,78 % |
Flujo de caja libre | -12,30 M | 32,48 % |
Información sobre la empresa
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Fundación
2011
Sitio web
Empleados
26
